TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32114543

Group type: EXPERIMENTAL
Intervention: PFD or PFDD
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: PFDD
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Preoperative frontal‐occipital horn ratio (FOHR)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Syrinx location spanning multiple spinal segments
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Scoliosis
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Smaller syrinx diameter
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Shorter preoperative syrinx length
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Smaller pB‐C2 distance
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Increased postoperative syrinx diameter
Number of subjects: 380

Group type: COMPARATOR
Intervention: PFD versus PFDD
Number of subjects: 380
Study: 34865318

Group type: EXPERIMENTAL
Intervention: Acyclovir nanofiber patch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo nanofiber patch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acyclovir cream
Number of subjects: 60
Study: 32118268

Group type: EXPERIMENTAL
Intervention: ENBAL
Number of subjects: 108

Group type: COMPARATOR
Intervention: 24h fasting
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fasting-induced epinephrine increase
Number of subjects: 108
Study: 32756661

Group type: EXPERIMENTAL
Intervention: Peanut oil
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Blend oil
Number of subjects: 251
Study: 36084000

Group type: EXPERIMENTAL
Intervention: High-SCFA diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-SCFA diet
Number of subjects: 20
Study: 615706097

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (EMLA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (moisturising cream)
Number of subjects: 22
Study: 35075816

Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention (40 min per day for 5/6 days per week)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention
Number of subjects: 160
Study: 34389012

Group type: EXPERIMENTAL
Intervention: Flexible e‐learning video approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: F2F lecture-based approach
Number of subjects: 36
Study: 34613454

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 392
Study: 33403727

Group type: EXPERIMENTAL
Intervention: Ciclesonide inhalation (343 µg/actuation) solution
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (0 µg/actuation)
Number of subjects: 224
Study: 32822968

Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 3

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 3
Study: 36222067

Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Psychological well-being practitioners (PWPs) delivering smoking cessation intervention
Number of subjects: 36
Study: 33737300

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 214
Study: 33714498

Group type: EXPERIMENTAL
Intervention: Dynamic Tape™ application on GM muscle adhering to the stretching method for Kinesio Tape® application (KG, n = 17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dynamic Tape™ application on GM muscle adhering to the stretching method suggested for DT (DG, n = 16)
Number of subjects: 33
Study: 32384504

Group type: EXPERIMENTAL
Intervention: Johnson's baby shampoo top‐to‐toe (No More Tears formula)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OCuSOFT Lid Scrub Original Foaming Eyelid Cleanser (OSO)
Number of subjects: 60
Study: 36146946

Group type: EXPERIMENTAL
Intervention: Guarana (125 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (65 mg/kg protein powder)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Caffeine (5 mg/kg)
Number of subjects: 25
Study: 34537120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg.kg‐1. h‐1 (Group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 15 mg.kg‐1. h‐1 (Group M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (Group S)
Number of subjects: 60
Study: 32649925

Group type: EXPERIMENTAL
Intervention: Antipsychotic monotherapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Psychological intervention (CBT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Antipsychotics plus psychological intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61
Study: 35773652

Group type: EXPERIMENTAL
Intervention: Corrective exercises based on the Alexander posture correction technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 34521466

Group type: EXPERIMENTAL
Intervention: Lycium barbarum polysaccharide (LBP) supplementation capsules
Number of subjects: 50

Group type: COMPARATOR
Intervention: Maltodextrin placebo capsules
Number of subjects: 50
Study: 616081502

Group type: EXPERIMENTAL
Intervention: topical 0.1% fluorometholone
Number of subjects: 41

Group type: COMPARATOR
Intervention: vehicle polyvinyl alcohol
Number of subjects: 41
Study: 33731664

Group type: EXPERIMENTAL
Intervention: Exercise condition (4 kcal·kg‐1·wk‐1, 8 KKW, 12 KKW, or 20 KKW)
Number of subjects: 414
Study: 32467540

Group type: EXPERIMENTAL
Intervention: DMTAC service (four or more visits) in addition to normal clinic visits
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal clinic visits with consultations by a medical officer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (control and intervention)
Number of subjects: 100
Study: 34855996

Group type: EXPERIMENTAL
Intervention: Surgical excision of ulcerated skin cancer
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Surgical excision of ulcerated skin cancer with wounds healing by secondary intention
Number of subjects: 148
Study: 32621467

Group type: EXPERIMENTAL
Intervention: Lornoxicam (16 mg/day for 2 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Xefocam (lyophilisate for preparation of solution for intravenous and intramuscular injection)
Number of subjects: 108
Study: 33616618

Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 0
Study: 32497219

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 35283261

Group type: EXPERIMENTAL
Intervention: EX+DWL (exercise combined with dietary weight loss)
Number of subjects: 0

Group type: COMPARATOR
Intervention: WWE (Walk With Ease) standard of care self-management program
Number of subjects: 0
Study: 32553589

Group type: EXPERIMENTAL
Intervention: Non-surgical management (NSM) including radiation therapy (71% of NSM), hormonal therapy (25% of NSM), and both (4% of NSM)
Number of subjects: 112469

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 112469

Group type: EXPERIMENTAL
Intervention: Non-surgical management (NSM)
Number of subjects: 112469
Study: 35867804

Group type: EXPERIMENTAL
Intervention: istaroxime 1.0 - 1.5 μg/kg/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 34369043

Group type: EXPERIMENTAL
Intervention: Pre-pandemic social support
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pre-pandemic depressive symptoms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Life disruptions due to the pandemic
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Parents of color
Number of subjects: 100
Study: 35264615

Group type: EXPERIMENTAL
Intervention: Helmet ventilation (HV) during 6 minute walk test (6MWT)
Number of subjects: 20
Study: 34292427

Group type: EXPERIMENTAL
Intervention: Benign molecular test result
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Suspicious molecular test result
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 252
Study: 32539783

Group type: EXPERIMENTAL
Intervention: Exenatide for 12 weeks
Number of subjects: 38
Study: 35656943

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 vaccine
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (non-vaccinated COVID-19 negative patients)
Number of subjects: 187
Study: 33280101

Group type: EXPERIMENTAL
Intervention: Temporalis muscle measurements
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Development of temporal crest
Number of subjects: 50
Study: 33216623

Group type: EXPERIMENTAL
Intervention: Nutrition supplementation (whey protein, fish oil, vitamin D)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Physical exercise (resistance and aerobic exercise)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Nutrition combined with exercise
Number of subjects: 241

Group type: COMPARATOR
Intervention: Routine consultation
Number of subjects: 241
Study: 33137581

Group type: EXPERIMENTAL
Intervention: Mixed Focus (internal plus external)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: External Focus
Number of subjects: 90
Study: 35317850

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection to the vocal cord contralateral to the lesion
Number of subjects: 20

Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 20
Study: 34971304

Group type: EXPERIMENTAL
Intervention: Local application of bupivacaine (3 mL of 0.5% plain bupivacaine hydrochloride)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (3 mL)
Number of subjects: 40
Study: 33910138

Group type: EXPERIMENTAL
Intervention: Behavioral interventions designed to enhance self-regulation (executive functioning, emotion regulation, future-oriented thinking, approach biases)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 118
Study: 34934307

Group type: EXPERIMENTAL
Intervention: Esmolol 0.5 mg/kg for 5 min before anesthesia induction, maintained at 0.5 mg/kg/h
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Esmolol 1.0 mg/kg for 5 min before anesthesia induction, maintained at 2.0 mg/kg/h
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal saline 0.75 mL/kg/h for 5 min before anesthesia induction, maintained at 0.25 mL/kg/h
Number of subjects: 125
Study: 34569486

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Rituximab (500 mg/m2 + 2 for 6 cycles)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 131

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 131
Study: 33984668

Group type: EXPERIMENTAL
Intervention: Semi-structured physical activity intervention (60 min per meeting, 5 times per week, over 12 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supervised free play program (60 min per meeting, 5 times per week, over 12 months)
Number of subjects: 42
Study: 36130761

Group type: EXPERIMENTAL
Intervention: Early near vision correction with spectacles (+3.00 DS) prescribed for full-time wear, with intervention at 8 weeks corrected gestational age (Group B1) or 16 weeks corrected gestational age (Group B2).
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care - waiting until a problem is detected (Group A).
Number of subjects: 75
Study: 32126750

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol (CI group)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Intermittent bolus injection of propofol (BI group)
Number of subjects: 232
Study: 34817126

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) - 660 nm, 100 mW, 177 J/cm2, 5 s, 0.5 J per point
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% (Control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (PBM and Control)
Number of subjects: 34
Study: 33199490

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Bevacizumab (cohort A, n = 50)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone (cohort B, n = 30)
Number of subjects: 80
Study: 32053162

Group type: EXPERIMENTAL
Intervention: Heading group (10 headers with soccer balls at 25 mph)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Kicking-control group (10 kicks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 67
Study: 35534494

Group type: COMPARATOR
Intervention: Prednisolone 1 mg/kg/day (max 60 mg/day) alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day (max 60 mg/day) with methotrexate 0.3 mg/kg/week for 9 months
Number of subjects: 44
Study: 33908665

Group type: EXPERIMENTAL
Intervention: Nicotine mini-lozenge
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Nicotine mini-lozenge + Reduction counseling
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Reduction counseling
Number of subjects: 577
Study: 34757134

Group type: EXPERIMENTAL
Intervention: Probiotic formula (Lactobacillus acidophilus LA‐5, Lactobacillus plantarum, Bifidobacterium lactis BB‐12, Saccharomyces boulardii) administered as two sachets twice daily for 15 days
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Probiotic formula
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 32009500

Group type: EXPERIMENTAL
Intervention: PedsQL Family Impact Module
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Child self-report and proxy report surveys
Number of subjects: 58

Group type: COMPARATOR
Intervention: Gastrostomy tube
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ventilation support
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nusinersen use
Number of subjects: 58

Group type: COMPARATOR
Intervention: Spinal surgery
Number of subjects: 58
Study: 91005492

Group type: EXPERIMENTAL
Intervention: Immune gamma-globulin given to the neonates born of mothers with hepatitis A
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pregnant women with hepatitis A
Number of subjects: 34
Study: 35717262

Group type: EXPERIMENTAL
Intervention: Broad-spectrum message and chart
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Overall-prescribing message with a chart
Number of subjects: 1851
Study: 33050928

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg administered subcutaneously every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35191525

Group type: EXPERIMENTAL
Intervention: iACT group
Number of subjects: 182

Group type: COMPARATOR
Intervention: WLC group
Number of subjects: 182
Study: 33743799

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (1 unit, 200-399 mL)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Number of subjects: 1000
Study: 32726793

Group type: EXPERIMENTAL
Intervention: Supervised exercise training as part of a 19-week rehabilitation program (3 weeks inpatient, 16 weeks at home).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Supervised exercise training as part of a 19-week rehabilitation program.
Number of subjects: 45
Study: 35900726

Group type: EXPERIMENTAL
Intervention: Talazoparib, 1 mg orally daily and avelumab, 10 mg/kg intravenously every 2 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Talazoparib and avelumab
Number of subjects: 35
Study: 34116652

Group type: EXPERIMENTAL
Intervention: 5-gene prognostic signature (TPM1, SLC2A1, CDCA8, ATG10, HOXD9)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Risk score based on the 5-gene signature
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating the 5-gene signature and clinical features
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: GSEA analysis of low- and high-risk groups
Number of subjects: 374
Study: 32871992

Group type: EXPERIMENTAL
Intervention: Comprehensive psychosomatic promotion
Number of subjects: 80
Study: 33557654

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 15
Study: 32144172

Group type: EXPERIMENTAL
Intervention: iStep‐MS intervention (four therapist‐led sessions over 12 weeks, supported by a handbook and pedometer)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iStep‐MS intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 60
Study: 35999653

Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drops
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 34418399

Group type: EXPERIMENTAL
Intervention: Non-immunogenic staphylokinase (10 mg)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, maximum 90 mg)
Number of subjects: 336
Study: 32707294

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for Children (n = 103)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control condition (n = 40)
Number of subjects: 143
Study: 34882313

Group type: EXPERIMENTAL
Intervention: Physical Manipulation Pulmonary Rehabilitation (PMPR) combined with Conventional Pulmonary Rehabilitation (CVPR)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional Pulmonary Rehabilitation (CVPR) only
Number of subjects: 86
Study: 33197681

Group type: EXPERIMENTAL
Intervention: Situational simulation training
Number of subjects: 92

Group type: COMPARATOR
Intervention: Online teaching
Number of subjects: 92
Study: 32854613

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 40
Study: 33141078

Group type: EXPERIMENTAL
Intervention: Aquatic exercises (16 weeks, twice per week, 45 min/session)
Number of subjects: 120
Study: 34999324

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation for one year
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 600
Study: 33952398

Group type: EXPERIMENTAL
Intervention: SDS group (subcutaneous sufentanil and dexmedetomidine)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SDI group (intravenous sufentanil and dexmedetomidine)
Number of subjects: 97

Group type: COMPARATOR
Intervention: SS group (subcutaneous sufentanil)
Number of subjects: 97

Group type: COMPARATOR
Intervention: SI group (intravenous sufentanil)
Number of subjects: 97
Study: 35534903

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low-flow nasal cannula (LFNC)
Number of subjects: 94
Study: 32960521

Group type: EXPERIMENTAL
Intervention: GnRHa trigger
Number of subjects: 210

Group type: COMPARATOR
Intervention: hCG trigger
Number of subjects: 210
Study: 35799113

Group type: EXPERIMENTAL
Intervention: Potentially Inappropriate Medications (PIMs)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Potential Prescribing Omissions (PPOs)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Number of medications
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Presence of at least one PIM
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Presence of at least one PPO
Number of subjects: 461
Study: 33452350

Group type: EXPERIMENTAL
Intervention: Volatile anesthesia (sevoflurane/remifentanil)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) (propofol/remifentanil)
Number of subjects: 136

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Volatile anesthesia
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both TIVA and Volatile anesthesia
Number of subjects: 136
Study: 34910219

Group type: EXPERIMENTAL
Intervention: Second 1-g TXA
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 32239164

Group type: EXPERIMENTAL
Intervention: MMV390048 80 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MMV390048 40 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MMV390048 120 mg (predicted)
Number of subjects: 39
Study: 36470231

Group type: EXPERIMENTAL
Intervention: tACS (transcranial alternating current stimulation) targeting the left fronto-parietal network for 20 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) targeting the left dorsolateral prefrontal cortex for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation for 20 minutes
Number of subjects: 20
Study: 33201300

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) for solitary plasmacytoma
Number of subjects: 42
Study: 32520718

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention
Number of subjects: 3995
Study: 36059420

Group type: EXPERIMENTAL
Intervention: Combination of apatinib
Number of subjects: 116

Group type: COMPARATOR
Intervention: Gemcitabine and oxaliplatin
Number of subjects: 116
Study: 32542334

Group type: EXPERIMENTAL
Intervention: Novel botanical formula (6 mg, 10 mg, or 14 mg of lutein)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 10 mg lutein formula
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 14 mg lutein formula
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Novel botanical formula (all doses)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 360
Study: 34843674

Group type: EXPERIMENTAL
Intervention: Home-based delivery (HBD)
Number of subjects: 2489

Group type: EXPERIMENTAL
Intervention: Adherence clubs (AC)
Number of subjects: 2489

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 2489
Study: 32129791

Group type: EXPERIMENTAL
Intervention: Workplace wellness program and guidelines-oriented hypertension management protocol with community health center intervention; duration: 24 months.
Number of subjects: 4166

Group type: COMPARATOR
Intervention: Usual care (control group); duration: 24 months.
Number of subjects: 4166
Study: 36217243

Group type: EXPERIMENTAL
Intervention: Systemic congruence couple therapy (CCT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Individual-based treatment-as-usual (TAU)
Number of subjects: 46